Triplet Regimen Shows Promise in Patients with Newly Diagnosed DLBCL
Leah SherwoodAggressive B-Cell Lymphoma | December 5, 2022
A combination of rituximab, lenalidomide, and ibrutinib produced a high overall response rate (ORR), and the triplet regimen with chemotherapy resulted in durable responses in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to results from the Smart Start study. The Smart Start study is the first study to treat newly diagnosed DLBCL with a targeted therapy combination before chemotherapy. The results were published in the Journal of Clinical Oncology in a paper by Jason Westin, MD, MS, of the University of Texas MD Anderson Cancer Center in Houston and colleagues. ...
Advertisement

Advertisement
Advertisement
Editorial Board

Expert Interviews

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

ACUTE MYELOID LEUKEMIA

October 12, 2022